|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
US11597706B2
(en)
|
2016-04-18 |
2023-03-07 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
CN110366549A
(zh)
|
2017-01-23 |
2019-10-22 |
基因泰克公司 |
作为白介素-1活性抑制剂的化合物
|
|
CA3059458A1
(en)
|
2017-05-24 |
2018-11-29 |
The University Of Queensland |
Novel compounds and uses
|
|
US11370776B2
(en)
|
2017-07-07 |
2022-06-28 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
|
|
MA56075A
(fr)
|
2017-07-07 |
2022-04-06 |
Inflazome Ltd |
Nouveaux composés de sulfonamide carboxamide
|
|
IL271259B2
(en)
|
2017-07-24 |
2024-06-01 |
Novartis Inflammasome Res Inc |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
EP3658538B1
(en)
*
|
2017-07-24 |
2023-04-19 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
UY37848A
(es)
|
2017-08-15 |
2019-03-29 |
Inflazome Ltd |
Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
|
|
WO2019034693A1
(en)
|
2017-08-15 |
2019-02-21 |
Inflazome Limited |
SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
|
|
MA49903A
(fr)
|
2017-08-15 |
2020-06-24 |
Inflazome Ltd |
Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
US12221434B2
(en)
|
2017-11-09 |
2025-02-11 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
SG11202003984UA
(en)
*
|
2017-11-09 |
2020-05-28 |
Inflazome Ltd |
Novel sulfonamide carboxamide compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803393D0
(en)
*
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166633A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
WO2019211463A1
(en)
|
2018-05-04 |
2019-11-07 |
Inflazome Limited |
Novel compounds
|
|
JP2021529780A
(ja)
|
2018-07-03 |
2021-11-04 |
ノバルティス アーゲー |
Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
|
|
WO2020010140A1
(en)
*
|
2018-07-03 |
2020-01-09 |
Novartis Inflammasome Research, Inc. |
Nlrp modulators
|
|
US20220267276A1
(en)
*
|
2018-07-03 |
2022-08-25 |
Novartis Ag |
Nlrp modulators
|
|
KR20210034596A
(ko)
|
2018-07-20 |
2021-03-30 |
에프. 호프만-라 로슈 아게 |
인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물
|
|
WO2020018970A1
(en)
|
2018-07-20 |
2020-01-23 |
Genentech, Inc. |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
BR112021002770A2
(pt)
|
2018-08-15 |
2021-05-04 |
Inflazome Limited |
compostos inovadores de sulfonamidaurea
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
JP2022505525A
(ja)
*
|
2018-10-24 |
2022-01-14 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
JP2022506898A
(ja)
|
2018-11-13 |
2022-01-17 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物
|
|
CN113015730A
(zh)
*
|
2018-11-13 |
2021-06-22 |
诺华股份有限公司 |
用于治疗与nlrp活性相关的病症的化合物和组合物
|
|
LT3880660T
(lt)
*
|
2018-11-13 |
2025-10-10 |
|
Junginiai ir kompozicijos, skirti gydyti su nlrp veikla susijusia būkles
|
|
JP2022507505A
(ja)
*
|
2018-11-16 |
2022-01-18 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
GB201819083D0
(en)
*
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
FI3911631T3
(fi)
|
2019-01-14 |
2025-02-03 |
Zydus Lifesciences Ltd |
Uusia substituoituja sulfonyyliureajohdannaisia
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
CN111848461A
(zh)
*
|
2019-04-29 |
2020-10-30 |
苏州大学 |
Nlrp3炎症小体抑制剂及其制备方法和应用
|
|
CA3141407A1
(en)
*
|
2019-06-17 |
2020-12-24 |
Charles A. Dinarello |
Method for treating asthma
|
|
WO2020254697A1
(en)
|
2019-06-21 |
2020-12-24 |
Ac Immune Sa |
Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
|
|
WO2021002887A1
(en)
*
|
2019-07-02 |
2021-01-07 |
Novartis Inflammasome Research, Inc. |
Gut-targeted nlrp3 antagonists and their use in therapy
|
|
KR102852270B1
(ko)
|
2019-07-17 |
2025-08-29 |
조마젠 바이오사이언시즈 엘티디 |
Nlrp3 조절제
|
|
KR20220064364A
(ko)
*
|
2019-07-17 |
2022-05-18 |
조마젠 바이오사이언시즈 엘티디 |
다발성 경화증(ms)의 치료를 위한 nlpr3 조절제로서의 n-((1,2,3,5,6,7-헥사하이드로-s-인다센-4-일)카바모일)-4,5,6,7-테트라하이드로벤조푸란-2-설폰아미드 유도체 및 관련 화합물
|
|
US20220289766A1
(en)
|
2019-08-16 |
2022-09-15 |
Inflazome Limited |
Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
CN111100042B
(zh)
*
|
2019-11-18 |
2022-05-31 |
苏州诚和医药化学有限公司 |
一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法
|
|
CN111018750B
(zh)
*
|
2019-12-19 |
2022-05-27 |
苏州诚和医药化学有限公司 |
一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
WO2021165245A1
(en)
|
2020-02-18 |
2021-08-26 |
Inflazome Limited |
Compounds
|
|
CN115605209B
(zh)
*
|
2020-03-16 |
2024-12-17 |
祖玛珍生物科学有限公司 |
Nlrp3调节剂
|
|
EP4121032A1
(en)
|
2020-03-19 |
2023-01-25 |
Softhale NV |
Method for the treatment nlrp3-associated diseases
|
|
CN115768749B
(zh)
|
2020-06-11 |
2024-04-19 |
辰欣药业股份有限公司 |
二甲基亚磺酰亚胺衍生物
|
|
IL299084A
(en)
|
2020-06-19 |
2023-02-01 |
Ac Immune Sa |
History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
JP2024508728A
(ja)
*
|
2021-02-10 |
2024-02-28 |
ハンジョウ イノゲート ファーマ カンパニー リミテッド |
Ｎｌｒｐ３阻害剤としての化合物
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
CN116635374B
(zh)
*
|
2021-05-10 |
2025-05-06 |
康百达（四川）生物医药科技有限公司 |
酰胺衍生物及其应用
|
|
CN118355000A
(zh)
*
|
2021-12-03 |
2024-07-16 |
辰欣药业股份有限公司 |
二甲基亚磺酰亚胺衍生物的盐型及晶型
|
|
JP2025502732A
(ja)
|
2021-12-22 |
2025-01-28 |
エーシー・イミューン・エス・アー |
ジヒドロオキサゾール誘導体化合物
|
|
CA3261036A1
(en)
|
2022-07-14 |
2024-01-18 |
Ac Immune Sa |
Pyrrolotriazine and imidazotriazine derivatives used as NLRP3 inflammatory pathway modulators
|
|
EP4562009A1
(en)
|
2022-07-28 |
2025-06-04 |
AC Immune SA |
Novel compounds
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
TW202502344A
(zh)
|
2023-06-02 |
2025-01-16 |
美商默沙東有限責任公司 |
作為nod樣受體蛋白3抑制劑之5,6不飽和雙環雜環
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|